FIGURE 3.
There was no significant difference in the 3-year overall survival rate between the wild-type KRAS group and the mutant type KRAS group (94.7% vs 92.3%, P = 0.249). KRAS = Kirsten rat sarcoma viral oncogene homolog.
There was no significant difference in the 3-year overall survival rate between the wild-type KRAS group and the mutant type KRAS group (94.7% vs 92.3%, P = 0.249). KRAS = Kirsten rat sarcoma viral oncogene homolog.